BackTeladoc Health Overview
Teladoc Health Inc

Teladoc Health Target Price

Analysts' average 12-month price target for Teladoc Health is $8.8.

Get informed when a big investor buys or sells

+ Follow

Share Price

$6.47

Average Target Price

$8.8336.5% upside

3 analysts in the last 4 months

High: $11 | Low: $7.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-30JefferiesBrian Tanquilut$823.6% upsideOpen
2026-07-30Evercore ISI$7.515.9% upsideOpen
2026-07-21Canaccord GenuityRichard Close$1170% upsideOpen
2026-04-08Evercore ISI$67.3% downsideOpen
2026-03-10Deutsche BankGeorge Hill$1170% upsideOpen
2026-02-26Stifel NicolausDavid Grossman$67.3% downsideOpen
2026-02-26Wells FargoStephen Baxter$67.3% downsideOpen
2026-01-16Goldman Sachs$823.6% upsideOpen
2026-01-09Goldman SachsDavid Roman$939.1% upsideOpen
2025-12-08Barclays$8.531.4% upsideOpen
2025-10-30Stifel NicolausDavid Grossman$823.6% upsideOpen
2025-07-30Raymond James$1054.6% upsideOpen
2024-12-04Piper SandlerJessica Tassan$13100.9% upsideOpen
2024-10-31CitigroupDaniel Grosslight$1170% upsideOpen
2024-10-30Evercore ISIElizabeth Anderson$939.1% upsideOpen
2024-08-06Piper SandlerJessica Tassan$1054.6% upsideOpen
2024-06-11BarclaysSteve Valiquette$20209.1% upsideOpen
2024-05-31JefferiesGlen Santangelo$1054.6% upsideOpen
2024-05-20JefferiesGlen Santangelo$14116.4% upsideOpen
2024-04-05Deutsche BankGeorge Hill$18178.2% upsideOpen
2023-04-12StephensJeff Garro$25286.4% upsideOpen
2022-12-13Citigroup$33410% upsideOpen
2022-09-28RBC Capital$35441% upsideOpen
2022-09-27Deutsche Bank$31379.1% upsideOpen
2022-07-31BarclaysSteve Valiquette$42549.1% upsideOpen
2022-07-28Barclays$40518.2% upsideOpen
2022-07-28Oppenheimer$55750.1% upsideOpen
2022-07-28Piper SandlerJessica Tassan$40518.2% upsideOpen
2022-07-28Evercore ISIElizabeth Anderson CFA$28332.8% upsideOpen
2022-06-29Stifel Nicolaus$36456.4% upsideOpen
2022-05-26Goldman Sachs$55750.1% upsideOpen
2022-05-18Piper SandlerJessica Tassan$42549.1% upsideOpen
2022-04-28Craig-Hallum$30363.7% upsideOpen
2022-04-28Canaccord Genuity$50672.8% upsideOpen
2022-04-28Deutsche Bank$44580.1% upsideOpen
2022-04-28RBC Capital$65904.6% upsideOpen
2022-04-28Citigroup$43564.6% upsideOpen
2022-04-28Credit Suisse$35441% upsideOpen
2022-04-28Needham$48641.9% upsideOpen
2022-04-28Leerink Partners$35441% upsideOpen
2022-04-28Credit SuisseJonathan Yong$35441% upsideOpen
2022-04-28BarclaysSteven Valiquette$45595.5% upsideOpen
2022-04-28Wells FargoStan Berenshteyn$40518.2% upsideOpen
2022-04-28Evercore ISIElizabeth Anderson CFA$30363.7% upsideOpen
2022-04-28Leerink PartnersStephanie Davis$35441% upsideOpen
2022-04-28RBC CapitalSean Dodge$65904.6% upsideOpen
2022-04-27Robert W. BairdVikram Kesavabhotla$38487.3% upsideOpen
2022-03-19Cowen & Co.Charles Rhyee$941352.9% upsideOpen
2022-02-28JefferiesGlen Santangelo$821167.4% upsideOpen
2022-02-28Berenberg BankDev Weerasuriya$1412079.3% upsideOpen

Teladoc Health (TDOC) FAQ

Teladoc Health's target price stands at $8.8. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $8.8 for TDOC implies 36.5% upside versus today's price ($6.47). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Teladoc Health's target price evolved across reporting periods, while the comparison chart places TDOC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Teladoc Health's reading of $8.8 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.